The Food and Drug Administration Friday expanded the approved uses for Vekury (remdesivir) to include non-hospitalized patients aged 12 and older who test positive for SARS-CoV-2, weigh at least 88 pounds and are at high risk of progressing to severe COVID-19. The agency also authorized emergency use of the drug for high-risk, non-hospitalized pediatric patients who weigh less than 88 but more than 8 pounds, including patients under age 12. The drug previously was limited to hospitalized patients. The expanded uses are based on results from a clinical trial that showed the drug reduced hospitalizations in high-risk, non-hospitalized patients. For more information, see the updated provider and patient fact sheets.

In other news, the FDA last week issued an emergency use authorization for another over-the-counter COVID-19 test. It said the MaximBio ClearDetect COVID-19 Antigen Home Test delivers results in 15 minutes.

 

Related News Articles

Headline
The Centers for Disease Control and Prevention Dec. 11 released a report that found last year’s version of the COVID-19 vaccine was 76% effective in preventing…
Headline
The AHA provided recommendations to the Food and Drug Administration Dec. 1 in response to a request for information on the measurement and evaluation of…
Headline
The Food and Drug Administration has identified a Class I recall of Baxter Life2000 Ventilation Systems due to a cybersecurity issue discovered through…
Headline
The Food and Drug Administration yesterday published an announcement from Otsuka ICU Medical saying that the company issued a voluntary recall for a mislabeled…
Headline
The Centers for Disease Control and Prevention will update its immunization schedules for the COVID-19 and chickenpox vaccines to adopt recent recommendations…
Headline
The Food and Drug Administration today issued a request for public comment on a series of questions regarding current approaches to evaluating artificial…